October 22, 2015
By Alex Keown, BioSpace.com Breaking News Staff
BOSTON – As many biotech companies will soon begin releasing earnings statements, the Boston Business Journal put together a quick list of how much companies with ties to Boston spent on research and development.
The Journal said the ranking of R&D dollars spent as a percentage of total expenses, is meant to show “how much effort companies are putting” toward the goal of new drug development. Each of the companies ranked have a market valuation of more than $1 billion.
• ZIOPHARM Oncology, Inc., with a market value of $1.4 billion, spent $99 million on research and development for the past fiscal year, which ended June 30. That represents 85 percent of total company expenses.
• Cambridge, Mass.-based Agios Pharmaceuticals , with a market value of $2.6 billion, reported total R&D costs of $129 million for the past fiscal year, which ended June 30. That represents 83 percent of total company expenses.
• Alnylam Pharmaceuticals , with a market capitalization of $7.1 billion, spent $227 million on research and development for the past fiscal year, which ended June 30. That represents 82 percent of the company’s total expenses.
• Celldex Therapeutics, Inc. , which has a market value of $1.34 billion, spent $105 million on research and development for the past fiscal year, which ended June 30. The R&D costs represented 80 percent of total company expenses.
• Cambridge, Mass.-based bluebird bio , with a market capitalization of $3 billion, spent $105 million on R&D costs for the past fiscal year, which ended June 30. That represented 76 percent of the company’s total expenses.
• SAGE Therapeutics with a market capitalization of $1.4 billion, spent $47milion on research and development for the past fiscal year, which ended June 30. That represented 74 percent of total company expenses.
• Tesaro , with a market value of $1.9 billion, spent $132 million on research and development for the past fiscal year, which ended June 30. That represented 73 percent of the company’s total expenses.
• Radius Health , based in Waltham, Mass., spent $53 million on research and development for the past fiscal year, which ended June 30. That was about 73 percent of total costs. Radius has a market capitalization of $2.7 billion.
• Momenta Pharmaceuticals, Inc. spent $110 million on R&D for the past fiscal year, which ended June 30. The R&D costs were 72 percent of the company’s total expenses. The company has a market value of $1.1 billion.
• Cambridge, Mass.-based Vertex Pharmaceuticals spent $832 million on R&D for the past fiscal year, which ended June 30. The costs were 68 percent of the company’s total expenses. Vertex has a market value of $28 million.
• Sarepta Therapeutics , based in Waltham, Mass., spent $121 million on research and development for the past fiscal year, which ended June 30. That was 66 percent of the company’s total expenses. Sarepta has a market capitalization of $1.2 billion.
• Alkermes , which has market capitalization of $9.3 billion, spent $311 million on research and development for the past fiscal year, which ended June 30. The R&D costs were 51 percent of Alekermes’ total expenses.
• Dyax Corporation , based in Burlington, Mass., which has a market value of $4 billion, spent $45 million on research and development for the past fiscal year, which ended June 30. The R&D costs were 50 percent of the company’s total expenses.
• Ironwood Pharmaceuticals , based in Cambridge, spent $108 million on research and development for the past fiscal year, which ended June 30. The total R&D costs were 47 percent of the company’s total expenses. Ironwood has a market value of $1.6 billion.
• Cambridge-based Ariad Pharmaceuticals, Inc. , which has a market value of $1.34 billion, spent $138 million on research and development for the past fiscal year, which ended June 30. Total R&D costs were 47 percent of the company’s total expenses.
• Biogen Idec, Inc. , with a market value of $64 billion, spent $1.87 billion on R&D for the past fiscal year, which ended June 30. The R&D costs were 42 percent of Biogen’s total expenses.
• Shire Pharmaceuticals , with a market capitalization of $27 billion, spent $1.4 billion on R&D for the past fiscal year, which ended June 30. The R&D costs were 40 percent of the company’s total expenses.
• AMAG Pharmaceuticals, Inc. spent $28 million on research and development for the past fiscal year, which ended June 30. The R&D expense was 19 percent of total company expenses.
